Syncom Formulations (India) Ltd. (SYNCOMF) — NSE Stock Analysis

Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic. Share price: ₹14.24.

Company Overview

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It provides life care, evolve, and right nutrition products under the Cratus brand. In addition, the company engages in the trading of commodities and renting of properties. It also exports its products. The company offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.

Valuation Snapshot

Market cap: —
P/E: —
P/B: —
ROE: —

Blanket Finance is not a SEBI-registered investment adviser or research analyst. This content is for educational and informational purposes only.